Keiretsu Forum-MST to host biotech investability panel at U.S. BioTech Day

Keiretsu Forum-MST will lead a panel at U.S. BioTech Day 2026 on Nov. 16 in Pennsylvania, focusing on what early-stage biotech companies must prove to attract capital. The session will examine leadership, governance, milestone planning and investor readiness as founders and investors weigh whether promising science can become a financeable business.

Why it matters: - Early-stage biotech companies often have promising science but still struggle to raise capital. - The panel will focus on what investors look for beyond technical data, including leadership, governance, execution and milestone planning. - The discussion is aimed at helping founders understand what must be proven before a financing round opens. - The session is also meant to help investors assess technical, regulatory, commercial and execution risk.

What happened: - Keiretsu Forum-MST will host a panel at U.S. BioTech Day 2026, set for Nov. 16-17, 2026, at Valley Forge Casino Resort & Convention Center in Pennsylvania. - The panel, “Finance Strategy: Good Science Is Not Enough. Early-Stage Biotech Companies Must Be Investable At All Milestones,” will run Monday, Nov. 16, from 9:00-9:45 a.m. - Howard Lubert, president of Keiretsu Forum-MST, will moderate the discussion. - The registration page is available at U.S. BioTech Day registration.

The details: - The panel will examine the gap between scientific assets and financeable biotech companies. - Discussion topics include investor expectations beyond the pitch deck. - The session will address how leadership and governance affect investor confidence. - Panelists will discuss how to define a financeable value-inflection point. - The conversation will cover why follow-on capital should not be treated as guaranteed. - The panel will also consider when licensing, strategic partnerships or asset sales may be more realistic than building a fully integrated company. - Howard Lubert said scientific differentiation may open the door with investors, but it does not close the round. - Lubert said early-stage biotech companies need to show they can convert scientific promise into measurable value. - Lubert said that requires the right leadership, execution strategy and discipline before capital is raised. - Panelist Christian Haller, CEO of CorIT Medical, will bring founder and company-builder experience from early-stage commercialization, investor engagement and venture development. - Panelist Benjamin R. Cowen, PhD, MBA, CEO of TicTwo Therapeutics, brings 25 years of pharmaceutical and biotech experience across business development, strategic planning, R&D portfolio management, marketing and sales. - TicTwo Therapeutics is a preclinical-stage biotech company developing TYK2 inhibitors for neuroinflammatory and neurodegenerative diseases. - Cowen previously led ImmunoMet Therapeutics from a preclinical-stage R&D organization into a clinical-stage biotech company. - Cowen raised about $30 million and advanced a first-in-class lead molecule through Phase 1 studies and into Phase 2a. - Panelist Krystle Karoscik, PhD, CEO and board director of INNOVOTEX Inc., has nearly two decades of experience translating breakthrough science into commercially viable and financeable assets. - Karoscik’s background includes translational research, clinical development, venture creation and portfolio strategy across therapeutics, pediatric innovation and platform technologies. - Panelist Maureen L. Mulvihill, PhD, president and CEO of Actuated Medical, is a medical technology entrepreneur and the 2020 Life Sciences Pennsylvania CEO of the Year. - Mulvihill has more than 20 years of experience building, funding and commercializing medical technologies. - Under Mulvihill’s leadership, Actuated Medical has secured more than $50 million in non-dilutive funding. - Actuated Medical has built a portfolio of 43 patents. - Actuated Medical has achieved nine FDA 510(k) clearances. - Actuated Medical has received two Tibbetts Awards for SBIR commercialization excellence. - Mulvihill also serves on the boards of AdvaMEd, AdvaMed Accel and Life Sciences Pennsylvania.

Between the lines: - The panel’s framing suggests investors are placing more weight on company-building discipline than on science alone. - The emphasis on licensing, partnerships and asset sales signals that not every biotech idea is expected to become a fully integrated company. - The roster of panelists blends founder, clinical, commercial and financing experience, which reinforces the session’s practical focus. - Keiretsu Forum-MST is using the event to highlight its role in early-stage investing and diligence. - The organization says its members have invested $172 million-plus in more than 300 companies over the past 16 years.

What's next: - The panel will take place during U.S. BioTech Day 2026 on Nov. 16. - Attendees are expected to hear practical guidance on investor readiness, milestone planning and financing strategy. - The discussion may also help founders decide whether to pursue fundraising, partnerships or asset monetization first.

The bottom line: - In biotech, strong science is only the starting point. Investors want evidence that a company can turn that science into a disciplined, financeable plan.